Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27909987 | 1.00 | HDAC2 (0.45) | HDAC2SLC18A3SIGMAR1DPP4GAA | |
| Hydrochloric Acid SCHEMBL19995976 | 0.98 | HDAC2 (0.44) | HDAC2SLC18A3SIGMAR1DPP4GAA | |
| SCHEMBL29164408 | 0.84 | SLC18A3 (0.41) | HDAC2SLC18A3SIGMAR1DPP4GAA | |
| SCHEMBL27813615 | 0.82 | SLC18A3 (0.48) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL27704415 | 0.82 | HDAC2 (0.40) | HDAC2SLC18A3SIGMAR1DPP4 | |
| SCHEMBL18642722 | 0.81 | HDAC2 (0.42) | HDAC2SLC18A3SIGMAR1DPP4GAA | |
| SCHEMBL28336863 | 0.76 | MAP1LC3B (0.39) | MAP1LC3B | |
| SCHEMBL21654115 | 0.75 | HDAC2 (0.40) | HDAC2SLC18A3SIGMAR1DPP4 | |
| SCHEMBL21654272 | 0.75 | HDAC2 (0.38) | HDAC2SLC18A3SIGMAR1 | |
| SCHEMBL15723864 | 0.74 | HDAC2 (0.42) | HDAC2SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101914051-B | Synthesis method of 3-phenyl pyrroline derivatives with optical isomerism purity | JIAXING EPOCHEM PHARMTECH CO LTD | 2013-03-13 | — | — | CN | claimed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| EP-3515433-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| CN-110049977-A | As the lactams of potent and selective ROCK inhibitor, cyclic annular urea and carbamate and triazolone derivative | 百时美施贵宝公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-107207515-B | Pyrazine compounds for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2019-05-28 | — | — | CN | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| CN-107207515-A | Pyrazine compounds for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-102933079-B | catechol-O-methyltransferase inhibitors and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2016-02-17 | — | — | CN | disclosed |
| CN-105209457-A | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE DEUTSCHLAND | 2015-12-30 | — | — | CN | disclosed |
| CN-104557757-A | CETP inhibitors | MERCK & CO INC | 2015-04-29 | — | — | CN | disclosed |
| CN-104447603-A | CETP inhibitors | MERCK SHARP & DOHME | 2015-03-25 | — | — | CN | disclosed |
| CN-102304096-B | CETP inhibitors | MERCK SHARP & DOHME | 2014-12-03 | — | — | CN | disclosed |
| CN-102311401-B | CETP inhibitors | MERCK & CO INC | 2014-12-03 | — | — | CN | disclosed |
| CN-103987386-A | (RS) -2- (2-oxo-4-phenylpyrrolidin-1-yl) acetamide compounds with modulating activity with commensurate effects, pharmaceutical substances (variants) and uses thereof, compositions (variants) thereof | AKHAPKINA VALENTINA IVANOVNA | 2014-08-13 | — | — | CN | disclosed |
| CN-102933079-A | catechol-O-methyltransferase inhibitors and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME | 2013-02-13 | — | — | CN | disclosed |
| CN-102311401-A | CETP INHIBITORS | MERCK & CO INC | 2012-01-11 | — | — | CN | disclosed |
| CN-102304096-A | CETP inhibitors | MERCK SHARP & DOHME | 2012-01-04 | — | — | CN | disclosed |
| CN-1980904-A | CETP inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | HDAC2 1312/4885SLC18A3 14/4885SIGMAR1 297/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | HDAC2 1386/4885SLC18A3 13/4885SIGMAR1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.